EURURO Vol. 72 No. 4

563 656

relevant biomarkers to facilitate selection of novel targeted
therapies.
Author contributions: Sumanta K. Pal had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Pal, Sonpavade, Agarwal, Vogelzang, Srinivas,
Haas, Signoretti, McGregor, Jones, Lanman, Banks, Choueiri.
Acquisition of data: Pal, Lanman, Banks, Choueiri.
Analysis and interpretation of data: Pal, Jones, Lanman, Banks, Choueiri.
Drafting of the manuscript: Pal, Banks, Choueiri.
Critical revision of the manuscript for important intellectual content: Pal,
Sonpavade, Agarwal, Vogelzang, Srinivas, Haas, Signoretti, McGregor,
Jones, Lanman, Banks, Choueiri.
Statistical analysis: Pal, Banks.
Obtaining funding: None.
Administrative, technical, or material support: Lanman, Banks.
Supervision: Pal, Lanman, Banks, Choueiri.
Other: None.
Financial disclosures: Sumanta K. Pal certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: Lanman and
Banks are employees of Guardant, Inc.
Funding/Support and role of the sponsor: None[2_TD$DIFF].
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
.
References
[1]
.
[2]
[3]
[4]
.
[5]
.
[6]
[7]
.
[8]
.
[9]
.
[10]
[11]
.
[12]
[13]
.
[14]
[15]
[16]
.
[17]
.
[18]
[19]
.
[20]
[21]
[22]
[23]
.
[24]
.
[25]
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 5 7 – 5 6 4 563